IP Library Assignment 048521/0005
Patent Assignment
Reel/Frame 048521/0005

Release of Security Interest

Recorded: 2019-03-06 Pages: 15
Assignor
CRG SERVICING LLC
Executed: 2019-03-06
Assignee
SYNERGY PHARMACEUTICALS INC.
TWO EXECUTIVE DRIVE, SUITE 450, SOMERSET, NEW JERSEY, 08873
Covered Properties (50)
Compositions and Method for the Treatment and Detection of Colon Cancer
Formulations and Methods for Treating Ulcerative Colitis
Guanylate Cyclase Receptor Agonists for the Treatment of Tissue Inflammation and Carcinogenesis
Patent: 7,041,786 →
Application: 10/107,814 →
Publication: US 2003/0073628
Guanylate Cyclase Receptor Agonists for the Treatment of Tissue Inflammation and Carcinogenesis
Patent: 7,799,897 →
Application: 11/347,115 →
Publication: US 2006/0154868
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 7,879,802 →
Application: 12/133,344 →
Publication: US 2009/0048175
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 8,207,295 →
Application: 12/478,505 →
Publication: US 2010/0069306
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 8,034,782 →
Application: 12/504,288 →
Publication: US 2010/0093635
Agonists of Guanylate Cyclase Useful for the Treatment of Hypercholesterolemia, Atherosclerosis, Coronary Heart Disease, Gallstone, Obesity and Other Cardiovascular Diseases
Patent: 8,969,514 →
Application: 12/630,654 →
Publication: US 2010/0152118
Guanylate Cyclase Receptor Agonists for the Treatment of Tissue Inflammation and Carcinogenesis
Patent: 8,114,831 →
Application: 12/763,707 →
Publication: US 2011/0212884
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 8,716,224 →
Application: 13/010,267 →
Publication: US 2011/0160120
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 8,367,800 →
Application: 13/226,300 →
Publication: US 2011/0319343
Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Patent: 8,637,451 →
Application: 13/339,785 →
Publication: US 2012/0142614
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Patent: 9,616,097 →
Application: 13/421,769 →
Publication: US 2012/0237593
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 8,357,775 →
Application: 13/467,703 →
Publication: US 2012/0220526
Method of Inhibiting Bile Acid Absorption by Administering An Agonist of a Guanylate Cyclase Receptor
Patent: 9,089,612 →
Application: 13/513,224 →
Publication: US 2012/0289460
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 8,497,348 →
Application: 13/716,874 →
Publication: US 2013/0096071
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 8,569,246 →
Application: 13/731,483 →
Publication: US 2013/0116199
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 8,901,075 →
Application: 13/857,283 →
Publication: US 2014/0024605
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 8,664,354 →
Application: 13/955,710 →
Publication: US 2013/0310328
Process of Preparing Guanylate Cyclase C Agonists
Patent: 9,580,471 →
Application: 14/001,638 →
Publication: US 2014/0155575
Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Application: 14/137,256 →
Publication: US 2014/0121169
Agonists of Guanylate Cyclase and Their Uses
Patent: 9,545,446 →
Application: 14/189,645 →
Publication: US 2014/0242124
Compositions Useful For The Treatment Of Gastrointestinal Disorders
Patent: 9,486,494 →
Application: 14/207,749 →
Publication: US 2014/0287001
Agonists Of Guanylate Cyclase And Their Uses
Patent: 9,708,367 →
Application: 14/207,753 →
Publication: US 2014/0287002
Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 9,238,677 →
Application: 14/228,843 →
Publication: US 2014/0329738
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Application: 14/301,812 →
Publication: US 2015/0359749
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 9,266,926 →
Application: 14/528,257 →
Publication: US 2015/0057235
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 9,505,805 →
Application: 14/632,314 →
Publication: US 2015/0239934
Agonists of Guanylate Cyclase Useful for the Treatment of Hypercholesterolemia, Atherosclerosis, Coronary Heart Disease, Gallstone, Obesity and Other Cardiovascular Diseases
Patent: 9,814,752 →
Application: 14/742,456 →
Publication: US 2015/0283202
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 9,920,095 →
Application: 14/831,293 →
Publication: US 2016/0200766
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Patent: 9,610,321 →
Application: 14/845,644 →
Publication: US 2015/0366935
Ultra-Pure Agonists of Guanylate Cyclase C, Method of Making and Using Same
Application: 14/896,019 →
Publication: US 2016/0145307
Agonists of Guanylate Cyclase Useful for the Treatment of Opioid Induced Dysfunctions
Application: 14/944,499 →
Publication: US 2016/0367622
Agonists of Guanylate Cyclase Useful for Downregulation of Pro-Inflammatory Cytokines
Application: 15/026,560 →
Publication: US 2016/0235807
Agonists of Guanylate Cyclase Useful for the Treatment of Opioid Induced Dysfunctions
Application: 15/026,563 →
Publication: US 2016/0220630
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Patent: 9,914,752 →
Application: 15/049,740 →
Publication: US 2016/0243188
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Application: 15/184,574 →
Publication: US 2016/0367623
Compositions Useful for the Treatment of Gastrointestinal Disorders
Application: 15/272,873 →
Publication: US 2017/0000843
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Application: 15/297,688 →
Publication: US 2017/0029468
Agonists of Guanylate Cyclase and Their Uses
Application: 15/381,680 →
Publication: US 2017/0143789
Process of Preparing Guanylate Cyclase C Agonisys
Application: 15/405,787 →
Publication: US 2017/0129925
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Patent: 9,925,231 →
Application: 15/467,631 →
Publication: US 2017/0202903
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Patent: 9,919,024 →
Application: 15/467,648 →
Publication: US 2017/0202904
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Application: 15/471,462 →
Publication: US 2017/0209531
Agonists of Guanylate Cyclase and Their Uses
Application: 15/622,526 →
Publication: US 2017/0349630
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Application: 15/918,047 →
Publication: US 2018/0273586
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Application: 15/924,940 →
Publication: US 2018/0207229
Ultra-Pure Agonists of Guanylate Cyclase C, Method of Making and Using Same
Application: 16/000,251 →
Publication: US 2019/0002501
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Application: 16/018,278 →
Publication: US 2020/0009063
Agonists of Guanylate Cyclase and Their Uses
Application: 16/150,703 →
Publication: US 2019/0263861
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Oct 8, 2008
From: SHAILUBHAI, KUNWAR; JACOB, GARY S.
To: SYNERGY PHARMACEUTICALS, INC.
Reel/Frame 021645/0957 →
Assignment of Assignor's Interest Apr 1, 2013
From: SHAILUBHAI, KUNWAR; JACOB, GARY S.
To: SYNERGY PHARMACEUTICALS, INC.
Reel/Frame 030125/0152 →
Assignment of Assignor's Interest May 28, 2013
From: SHAILUBHAI, KUNWAR; JACOB, GARY S.
To: SYNERGY PHARMACEUTICALS, INC.
Reel/Frame 030495/0216 →
Assignment of Assignor's Interest Feb 24, 2020
From: SHAILUBHAI, KUNWAR; JACOB, GARY S.; GRIFFIN, PATRICK H.
To: SYNERGY PHARMACEUTICALS, INC.
Reel/Frame 051904/0302 →
Assignment of Assignor's Interest Apr 1, 2020
From: SYNERGY PHARMACEUTICALS, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 052285/0550 →
Assignment of Assignor's Interest Apr 9, 2020
From: SYNERGY PHARMACEUTICALS INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 052358/0134 →
Assignment of Assignor's Interest Jun 26, 2020
From: SYNERGY PHARMACEUTICALS INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 053055/0239 →
Assignment of Assignor's Interest Jul 30, 2020
From: SYNERGY PHARMACEUTICALS, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 053359/0680 →
Assignment of Assignor's Interest Sep 28, 2020
From: SYNERGY PHARMACEUTICALS, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 053903/0061 →
Assignment of Assignor's Interest Jan 4, 2021
From: SYNERGY PHARMACEUTICALS, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 054795/0458 →
Assignment of Assignor's Interest Mar 29, 2021
From: SYNERGY PHARMACEUTICALS, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 055748/0846 →
Assignment of Assignor's Interest Jun 29, 2021
From: SYNERGY PHARMACEUTICALS INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 056706/0105 →
Security Interest Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
Assignment of Assignor's Interest Oct 26, 2021
From: SYNERGY PHARMACEUTICALS INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 057914/0679 →
Assignment of Assignor's Interest May 9, 2022
From: SYNERGY PHARMACEUTICALS, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 059874/0544 →
Security Interest Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
Assignment of Assignor's Interest Jul 8, 2022
From: SYNERGY PHARMACEUTICALS, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 060466/0386 →
Assignment of Assignor's Interest Jul 8, 2022
From: SYNERGY PHARMACEUTICALS, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 060464/0415 →
Assignment of Assignor's Interest Jul 8, 2022
From: SYNERGY PHARMACEUTICALS INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 060463/0503 →
Security Agreement (First Lien) Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
Security Agreement (Second Lien) Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
Security Agreement (First Lien) Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
Security Agreement (Second Lien) Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
Release of Security Interest Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
U.S. Patent Security Agreement Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →